- Home
- BDTX vs RVPH Comparison
BDTX vs RVPH Comparison
Compare BDTX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- RVPH
- Stock Information
- Founded
- BDTX 2014
- RVPH 2006
- Country
- BDTX United States
- RVPH United States
- Employees
- BDTX N/A
- RVPH N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- RVPH Health Care
- Exchange
- BDTX Nasdaq
- RVPH Nasdaq
- Market Cap
- BDTX 132.5M
- RVPH 32.8M
- IPO Year
- BDTX 2020
- RVPH N/A
- Fundamental
- Price
- BDTX $2.58
- RVPH $0.36
- Analyst Decision
- BDTX Strong Buy
- RVPH Strong Buy
- Analyst Count
- BDTX 6
- RVPH 5
- Target Price
- BDTX $14.83
- RVPH $9.00
- AVG Volume (30 Days)
- BDTX 1.3M
- RVPH 2.6M
- Earning Date
- BDTX 08-05-2025
- RVPH 08-13-2025
- Dividend Yield
- BDTX N/A
- RVPH N/A
- EPS Growth
- BDTX N/A
- RVPH N/A
- EPS
- BDTX 0.09
- RVPH N/A
- Revenue
- BDTX $70,000,000.00
- RVPH N/A
- Revenue This Year
- BDTX N/A
- RVPH N/A
- Revenue Next Year
- BDTX N/A
- RVPH N/A
- P/E Ratio
- BDTX $29.29
- RVPH N/A
- Revenue Growth
- BDTX N/A
- RVPH N/A
- 52 Week Low
- BDTX $1.20
- RVPH $0.30
- 52 Week High
- BDTX $6.75
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- BDTX 60.64
- RVPH 31.07
- Support Level
- BDTX $2.43
- RVPH $0.35
- Resistance Level
- BDTX $2.72
- RVPH $0.40
- Average True Range (ATR)
- BDTX 0.18
- RVPH 0.07
- MACD
- BDTX -0.00
- RVPH -0.03
- Stochastic Oscillator
- BDTX 76.11
- RVPH 15.15
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.